Amgen posts higher third-quarter sales, but trims full-year estimate
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Amgen (AMGN) PT Lowered to $250 at Jefferies
November 3, 2021 8:03 AM EDTJefferies analyst Michael Yee lowered the price target on Amgen (NASDAQ: AMGN) to $250.00 (from $270.00) while maintaining a Buy rating.
The analyst commented, "here were, and still are, worries about AMGN numbers, given no big guidance raises all year, and co says ongoing... More
